At last year’s AD/PD meeting in Vienna, what is now the Consortium for Biomedical Research and AI in Neurodegeneration was an idea. By this year’s AD/PD in Copenhagen, C-BRAIN had become an operating ...
The blood-brain border has long stymied drug development for neurodegenerative diseases. In recent years, Denali, Roche, and others have designed molecular brain shuttles that ferry investigational ...
This interactive resource organizes decades of data on biomarkers for Alzheimer's disease. Biomarker measurements from the cerebrospinal fluid and blood are curated from the primary literature and ...
A selected list of scientific conferences relevant to researchers, clinicians and others interested in Alzheimer’s disease and related neurodegenerative disorders.
Affitope AD02 is a synthetic peptide of six amino acids that mimics the N-terminus of Aβ. AFFiRiS hypothesizes that this fragment enables exclusive recognition of Aβ without cross-reacting with APP, ...
This is an active immunotherapy strategy. ACC-001 is a conjugate of multiple short Aβ fragments linked to a carrier made of inactivated diphtheria toxin. Vanutide cridificar is designed to avoid the ...
NIH BRAIN and partner components intend to commit an estimated total of $2M in fiscal years 2025, 2026, 2027 to fund up to 8 new awards each year for this RFA, contingent upon annual appropriations.
Sergey Zubkov, Ph.D. Contact Information Sergey Zubkov, Ph.D. Odessa, Ukraine ...
The purpose of this notice is to inform the extramural community that effective May 08, 2026 NINDS will expire PA-25-150: Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial ...
It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
There was a new feeling in the air at the 12th Clinical Trials on Alzheimer’s Disease conference. It felt good: After decades of failure, the field might finally be turning a corner. The renewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results